Valneva SE: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Valneva SE Announces Sale of its Clinical Manufacturing Operations (CMO) in France to Biological E
Valneva SE announced the signing of a binding term sheet to sell its Clinical Manufacturing Operations (CMO) in Nantes to Biological E, an Indian biopharmaceutical company. The financial terms of the deal were not disclosed.
Latest Developments for Valneva SE
- Valneva SE issues FY 2014 revenue guidance
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
- Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
- Share this
- Digg this